BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings. The authors previously reported poor outcomes for patients who discontinued ibrutinib; however, long-term outcomes were not reported. METHODS: Data from 320 patients who received ibrutinib on clinical studies between 2010 and 2015 at The University of Texas MD Anderson Cancer Center were retrospectively analyzed. RESULTS: Long-term outcomes among patients with CLL after they discontinued ibrutinib were analyzed. Ninety of 320 patients (28%) who were treated on ibrutinib-based regimens discontinued ibrutinib. Of these, 80 had relapsed/refractory disease, and 10 were treatment-naive. The median time to discontinuation was 15 months (range, 1.2-54 months). After a median follow-up of 38 months after starting ibrutinib, 40 patients (44%) remained alive. Major reasons for ibrutinib discontinuation were intolerance (n 5 29; 32%), miscellaneous (n 5 28; 31%), progression (n 5 19; 21%), and Richter transformation (RT) (n 5 9; 10%). The median survival according to the reason for discontinuation was 33 months for ibrutinib intolerance, 11 months for miscellaneous causes, 16 months for progressive CLL, and 2 months for RT. Among the 19 patients who had progressive CLL, 42% responded to subsequent therapy. CONCLU-SIONS: Ibrutinib discontinuation was observed during therapy. Patients with CLL who had disease transformation had especially poor outcomes, whereas those who developed progressive disease during ibrutinib therapy had a median survival of <1.5 years. Survival was associated with the reason for discontinuation; patients who had progressive CLL had better survival compared with those who had disease transformation. Effective salvage strategies for patients with CLL who progress on ibrutinib therapy is of critical importance.
INTRODUCTION
Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is currently used as first-line and salvage therapy in patients with chronic lymphocytic leukemia (CLL). Combinations of ibrutinib with chemotherapy, anti-CD20 monoclonal antibodies, 1 or venetoclax and other novel agents are in clinical trials. Several studies [2] [3] [4] [5] have demonstrated that from 10% to 20% of patients who receive ibrutinib (in a frontline or relapsed/refractory [RR] setting) discontinue therapy after a median follow-up of 1 year because of either intolerance, disease progression, transformation, or other causes. A few groups previously reported that the survival of patients who discontinued ibrutinib because of disease transformation or early disease progression was poor. 2, 3, 6 Patients with B-cell CLL/lymphoma 6 (BCL6) abnormalities or complex karyotypes had an increased risk of disease progression on ibrutinib. 2 Survival after ibrutinib was associated with the reason for discontinuation and was very short in patients who discontinued ibrutinib because of CLL transformation and 18 months in those who discontinued because of disease progression. 2 The median follow-up of patients reported in those studies was <2 years. Development of progressive CLL is frequently associated with BTK mutations, 7, 8 most commonly a cysteine to serine mutation at codon 481 (C481S) or T474I, L528W or activating mutations in phospholipase-c-2 (PLCc2). 9 Rarely, ibrutinib-resistant subclones were detectable in patient samples before they received ibrutinib. 7 In addition, clones with del(8p), mutations in EP300, MLL2, and EIF2A and SH2 domain mutation (BTKT316A) have also been identified in resistant patients. 7, 10 Ibrutinib resistance 8, 11 is a growing concern as more patients receive this treatment. In this report, we present the long-term outcomes of patients with CLL who discontinued ibrutinib.
MATERIALS AND METHODS
We reviewed the charts of 90 patients who discontinued ibrutinib of the total 320 patients who received ibrutinibbased regimens on various clinical trials from 2010 through 2015 at The University of Texas MD Anderson Cancer Center (Supporting Table 1 ; see online supporting information). Treatment protocols and informed consents were approved by the Institutional Review Board, and trials were conducted in accordance with the declaration of Helsinki. Survival analysis was performed using the Kaplan-Meier method, and groups were compared using Cox regression. The cumulative incidence method was used to calculate time to ibrutinib discontinuation, taking into account competing risks.
RESULTS AND DISCUSSION
Overall, 90 patients (28%) discontinued ibrutinib after first-line (n 5 10 of 68) or salvage (n 5 80 of 252) ibrutinib therapy. Forty-seven patients (52%) received ibrutinib monotherapy, 31 (34%) received ibrutinib in combination with rituximab, and 12 (13%) received ibrutinib with bendamustine and rituximab. The median time to discontinuation of ibrutinib was 15 months (range, 1.2-54 months) overall, 19 months (range, 5-47 months) for previously untreated patients, and 14.5 months (range, 1.2-54 months) for patients with relapsed/refractory (R/R) disease. Reasons for and median time to discontinuing ibrutinib were: intolerance/toxicity (n 5 29 [32%]; 16 months), miscellaneous (9 stem cell transplantations, 8 other cancers, 2 sudden deaths, 6 sepsis and previous comorbidities, and 3 unknown; n 5 28 [31%]; 10.4 months), progressive CLL (n 5 19 [21%]; 22.3 months), disease transformation (7 diffuse large B-cell lymphomas, 1 histiocytic sarcoma, and 1 plasmablastic lymphoma; n 5 9 [10%]; 13.2 months), and transition to commercial supply (n 5 5; 26 months). Among the 9 patients who discontinued for SCT, 4 were in complete remission and remained under observation after SCT. Reasons for discontinuation after first-line ibrutinib (n 5 10) were: disease transformation (n 5 2); intolerance (n 5 6; 3 atrial fibrillation and arrhythmias, 2 bleeding, and 1 pneumonia); transition to commercial supply (n 5 1), and death from an unknown cause (n 5 1). Reasons for discontinuation in patients with R/R disease (n 5 80) were: disease transformation (n 5 7), intolerance/toxicities (n 5 23; 7 diarrhea, 5 atrial fibrillation, 4 bleeding, 1 pneumonia, and 6 miscellaneous toxicities), disease progression (n 5 19), miscellaneous reasons (n 5 27), and transition to commercial supply (n 5 4). Clinical characteristics of the patients who discontinued ibrutinib for intolerance and CLL progression/transformation are summarized in Table 1 . Table 2 summarizes the clinical data at progression, survival outcomes, and causes of death in 28 patients who discontinued ibrutinib because of CLL progression (n 5 19) and/or disease transformation (n 5 9). On first-line ibrutinib, 2 patients developed Richter transformation (RT), whereas none had progressive, refractory CLL. Both patients who developed RT while receiving first-line ibrutinib had unmutated immunoglobulin heavy-chain variable region gene (IGHV) status (1 in VH3 and another in VH1-69), Rai stage I disease, overexpression of cluster of differentiation 38 (CD38) and f-chain-associated protein kinase 70 (Zap-70), and deletion of the short arm of chromosome 17 (del[17p]) by fluorescence in situ hybridization (FISH) before starting Original Article ibrutinib. Overall, the majority of patients had high-risk features before starting ibrutinib (91% had unmutated IGHV status, 41% had del[17p] by FISH, 35% had a complex karyotype, and 55% had advanced Rai stage disease). Next, we analyzed survival outcomes for patients after they discontinued ibrutinib. After a median followup of 38 months, 40 patients (44%) were alive at the time of last follow-up. The median overall post ibrutinib survival time was 20.6 months (Fig. 1A) . Survival according to the cause of discontinuation is shown in Figure 1B . Median survival of patients was 33 months for patients who discontinued ibrutinib because of intolerance/toxicities, 11 months for those who discontinued for miscellaneous reasons, 16 months in those with progressive disease, and 2.3 months in patients who developed CLL transformation (P < .0001). Patients with progressive CLL had superior survival than patients who developed RT (hazard ratio, 6.7; P < .0003). Survival of patients did not differ significantly according to prior treatment status Figure 1C . The cumulative incidence of discontinuing ibrutinib according to the reason for discontinuation is illustrated in Figure 1D . We also assessed responses to subsequent therapies among the 19 patients who developed progressive disease while receiving ibrutinib treatment. Eight of 19 patients (42%) responded to subsequent therapy. Among the 8 responders, 5 (62%) achieved a partial response on venetoclax-based therapy (3 of 5 also failed idelalisib before commencing venetoclax), 2 (25%) responded to ofatumumab monotherapy, and 1 (12%) received idelalisib with rituximab. Evaluation for BTK and PLCc2 mutations was performed in 2 patients at the time of CLL progression: 1 patient had a BTK mutation (C481S) after disease progression; another patient who progressed on both ibrutinib and venetoclax had B-raf proto-oncogene serine/threonine kinase (BRAF), tumor protein 53 (TP53). and F-box and WD repeat domain-containing 7 (FBXW7) mutations; however, a pretreatment mutational profile was not available for this patient.
Ibrutinib has significantly improved outcomes for patients with CLL. Nevertheless, there continue to be challenges with this treatment, because most patients achieve partial remission as the best response, treatment is continuous and indefinite, and some patients must discontinue treatment because of resistance or intolerance/ Figure 1 . Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib are illustrated. (A) Median overall survival was 20.6 months after the discontinuation of ibrutinib (n 5 90). (B) The survival of patients according to the cause of discontinuation is illustrated (median survival: toxicity, 33 months; disease progression, 16 months; disease transformation, 2.3 months; other causes, 11 months; and commercial supply, not reached). (C) Median survival is compared between patients who were previously untreated (not reached) and those with relapsed/refractory CLL (21 months; P 5 .41). (D) The cumulative incidence of ibrutinib discontinuation is illustrated. Most events occurred within the first 2 years of ibrutinib therapy. Except for transformation, the incidence of other causes of discontinuation (progression, intolerance, and miscellaneous reasons) continued to increase after 48 months (P 5 .0065).
toxicity. In prior reports, early ibrutinib discontinuation was associated with a poor outcome, and subsequent survival was correlated with the reason for discontinuation; patients who had disease transformation had very poor outcomes, 2, 3 whereas those who developed progressive CLL had a median survival of 17 months. 2 Similar to previous publications, 2 we have demonstrated that RT occurs relatively early during ibrutinib therapy, and the risk decreases significantly after 12 to 18 months on treatment; in contrast, there is an ongoing incidence of CLL progression and cessation of treatment because of toxicity during long-term follow-up. 12 The outcomes for patients who develop CLL progression remain poor; approximately 70% of patients who progress on ibrutinib will respond to venetoclax 13 ; however, the durability of these responses is not clear, and other salvage options are currently limited. Furthermore, the outcome of patients who develop RT while receiving ibrutinib remains very poor.
2 Therefore, the development of effective salvage strategies for patients who develop progression/RT while receiving ibrutinib therapy is of critical importance. Ideally, these strategies should be guided by knowledge of the molecular mechanisms of resistance in an individual patient. 8 Several molecular mutations associated with ibrutinib resistance have been identified, but whether these specifically predict for response to subsequent salvage therapy is unclear and should be systematically studied in the future. It is likely that the subclonal architecture in such patients is complex 7, 14, 15 and that sequential monotherapy with other targeted agents after the development of ibrutinib resistance will also produce the outgrowth of resistant subclones. For this reason, we and other groups are developing combination strategies for the treatment of patients with high-risk CLL. In addition, the increasingly likelihood of treatment discontinuation for toxicity over time and poor outcomes after discontinuation for intolerance argue for the importance of developing time-limited, combination therapy in all patients rather than relying on indefinite ibrutinib monotherapy.
In this study, 2 patients developed RT while receiving first-line ibrutinib, and they had poor outcomes with salvage therapy. It is unclear whether RT that occurs during ibrutinib therapy is molecularly distinct from RT that occurs de novo or after chemoimmunotherapy. It is also unclear whether BTK and/or other mutations play any role in the development of RT, because data are limited on sequencing performed from lymph node specimens taken at the time of transformation. In summary, as the use of ibrutinib treatment continues to increase in patients with CLL; it is essential to delineate the pattern of mutations and dynamics of clonal evolution in those patients who discontinue ibrutinib because of disease progression/ transformation and to identify pathways for therapeutic targeting to improve the survival outcomes for these patients. 
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